Discover how cladribine compares to S1P modulators in treatment-naive relapsing-remitting MS, keep reading to learn more.

Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

Aging and shifting hormone levels influence how MS changes over time, and the overlap of these factors during midlife can ...

Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...

The FDA approved use of the Atalante X robotic exoskeleton, which allows people with mobility issues to stand upright, for MS ...

Roche's late-stage trial of fenebrutinib, a multiple sclerosis drug candidate, met its primary goal. The trial demonstrated a significant reduction in annualized relapse rates compared to ...

How Long Does It Take to See a Neurologist? On average, older adults waited 34 days for a new visit to a neurologist after a referral, and nearly 20% waited more than 3 months, new Medicare data ...

LONDON — Previous research has shown that providing a clinically definite multiple sclerosis (MS) diagnosis often takes several weeks or even months. But new research suggests that a new "technology ...

What should healthcare providers consider when advising patients at risk of or diagnosed with MS regarding the use of exogenous hormones, such as oral contraceptives, and their potential impact on ...

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body's ...